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Abstract
Background: Early chronic kidney disease (CKD) is associated with increased cardiovascular (CV) risk but underlying
mechanisms remain uncertain. Arterial stiffness (AS) is associated with increased CV risk in advanced CKD, but it is unclear
whether AS is relevant to CV disease (CVD) in early CKD.
Study Design: Cross-sectional.
Setting and participants: 1717 patients with previous estimated glomerular filtration rate (eGFR) 59–30 mL/min/1.73 m2;
mean age 7369y, were recruited from 32 general practices in primary care.
Outcomes: Increased arterial stiffness.
Measurements: Medical history was obtained and participants underwent clinical assessment, urine and serum
biochemistry testing. Carotid to femoral pulse wave velocity (PWV) was determined as a measure of AS, using a VicorderTM
device.
Results: Univariate analysis revealed significant correlations between PWV and risk factors for CVD including age (r = 0.456;
p,0.001), mean arterial pressure (MAP) (r = 0.228; p,0.001), body mass index (r =20.122; p,0.001), log urinary albumin to
creatinine ratio (r = 0.124; p,0.001), Waist to Hip ratio (r = 0.124, p,0.001), eGFR (r =20.074; p = 0.002), log high sensitivity
c-reactive protein (r = 0.066; p = 0.006), HDL (r =20.062; p = 0.01) and total cholesterol (r =20.057; p = 0.02). PWV was higher
in males (9.6 m/sec vs.10.3 m/sec; p,0.001), diabetics (9.8 m/sec vs. 10.3 m/sec; p,0.001), and those with previous CV
events (CVE) (9.8 m/s vs. 10.3 m/sec; p,0.001). Multivariable analysis identified age, MAP and diabetes as strongest
independent determinants of higher PWV (adjusted R2 = 0.29). An interactive term indicated that PWV increased to a greater
extent with age in males versus females. Albuminuria was a weaker determinant of PWV and eGFR did not enter the model.
Limitations: Data derived from one study visit, with absence of normal controls.
Conclusion: In this cohort, age and traditional CV risk factors were the strongest determinants of AS. Albuminuria was a
relatively weak determinant of AS and eGFR was not an independent determinant. Long-term follow-up will investigate AS
as an independent risk factor for CVE in this cohort.
Citation: McIntyre NJ, Fluck RJ, McIntyre CW, Fakis A, Taal MW (2013) Determinants of Arterial Stiffness in Chronic Kidney Disease Stage 3. PLoS ONE 8(1): e55444.
doi:10.1371/journal.pone.0055444
Editor: Murielle Bochud, Lausanne University Hospital and University of Lausanne, Switzerland
Received July 11, 2012; Accepted December 30, 2012; Published January 30, 2013
Copyright:  2013 McIntyre et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a fellowship grant from Kidney Research UK and the British Renal Society, as well as an unrestricted educational grant
from Roche Products plc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: As regards potential competing interests the authors would like to clarify that the support from Roche Products plc was in the form of an
unrestricted educational grant. Specifically this means that Roche played no role whatever in the initiation, design or conduct of the study and have no ownership
of the data. The authors are not obligated to provide Roche with any publications prior to submission and are not required to seek approval from Roche for any
publications. The authors are therefore able to confirm unequivocally that the sponsorship from Roche does not alter their adherence to all the PLOS ONE policies
on sharing data and materials.
* E-mail: maarten.taal1@nhs.net
Introduction
Multiple epidemiological studies attest that chronic kidney
disease (CKD) is associated with increased cardiovascular risk
compared to the general population, and may account for up to
50% of all deaths in this group [1]. In many studies people with
early stage CKD are more likely to die from cardiovascular disease
than progress to end stage kidney disease (ESKD) [2]. Hallan [3]
reported that the risk of CKD progression is low until eGFR falls
below 30 ml/min/1.73 m2. In contrast even modest reductions in
eGFR are incrementally associated with reduced survival [4]. The
increased cardiovascular (CV) risk associated with advanced stages
of CKD cannot be explained by traditional risk factors alone, but
is attributable to a combination of traditional and non-traditional
factors [5,6]. Arterial stiffness (AS) has been identified as one non-
traditional risk factor associated with the large cardiovascular risk
burden in CKD [7,8]. Arterial stiffness in CKD is proposed to
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provoke an increase in systolic blood pressure (SBP) and pulse
pressure (PP). This in turn leads to an increase in ventricular
afterload, myocyte hypertrophy and reduced coronary perfusion,
resulting in systolic and diastolic dysfunction. Elevated systolic and
pulse pressures may also contribute to vascular damage, further
increasing CV risk [9].
Aortic pulse wave velocity (aPWV) is a measure of AS and has
predicted cardiovascular morbidity and mortality in a number of
populations including the healthy elderly and people with
hypertension, diabetes or ESKD on haemodialysis
[10,11,12,13,14]. On the other hand, data regarding the
relationship between AS and CKD in earlier stages appear
conflicting. Several studies have reported an increase in arterial
stiffness and CV risk associated with early CKD [15,16,17] but
others have not [18,19,20]. More data are therefore required
regarding the relationship between AS and markers of kidney
disease in early stage CKD. The aim of our study was to
investigate if previously identified determinants of AS are also
relevant in a population of predominantly elderly people with
CKD stage 3, representing the majority affected by CKD.
Study Population and Methods
Participants and Recruitment
We studied 1741 patients with CKD stage 3 recruited from
general practitioner (GP) practices. The methods have previously
been described in detail and are summarised here with emphasis
on the measurement of aPWV [21,22]. Participants were recruited
as part of the Renal Risk in Derby (RRID) study, a prospective
cohort study planned to continue for 10 years, with the aim of
studying renal and CV risk factors in patients with CKD stage 3 in
a primary care setting. Eligible participants were 18 years or over,
met the KDOQI criteria for CKD stage 3 (eGFR of 30–59 mL/
min/1.73 m2 on 2 or more occasions at least 3 months apart),
were able to give informed consent and attend their GP practice
for assessments. People who had previously received a solid organ
transplant or who were terminally ill (expected survival ,1 year)
were excluded. The RRID study is being conducted by a single
Nephrology Department, but participants were recruited directly
from 32 GP practices in Derbyshire, UK. Study visits were
conducted at participating GP practices by the researchers.
Twenty four participants were unable to have their aPWV
measured due to a combination of technical failure or inability of
the participant to lie at a 30 degree angle. Thus 1717 participants
with aPWV readings were included in this analysis.
Data Collection
First study visits were conducted from August 2008 to March
2010. Screening and baseline visits were combined due to the large
proportion of elderly participants and the logistical challenges
associated with conducting study visits in multiple primary care
centres. Participants were sent a medical questionnaire as well as 3
urine specimen bottles, and were asked not to eat cooked meat for
at least 12 hours prior to the assessment [23]. At the assessment
information on questionnaires was checked, anthropomorphic
measurements and blood pressure taken, and urine analysis was
performed. Blood and urine specimens were submitted for
biochemical analysis to a single laboratory.
Previous diabetes was defined by having a previous clinical
diagnosis according to WHO criteria [24]. Previous cardiovascular
event (CVE) was defined as subject reported myocardial infarc-
tion, stroke, transient ischaemic attack, revascularisation or
amputation due to peripheral vascular disease, or aortic aneurysm.
Anaemia was defined as hemoglobin ,11.5 g/dL for women and
,13.5 g/dL for men. Obesity was defined as BMI.30 kg/m2.
Central fat distribution was defined as a waist to hip ratio (WHR)
of $0.9 for men or $0.8 for women [25].
Blood pressure. Blood pressure (BP) was measured after a
minimum of five minutes rest in the sitting position, using a
calibrated oscillometric device, recommended by the British
Hypertension Society (Digital Blood Pressure Monitor Model
UA-767, A&D Instruments Ltd, Abingdon, UK). A single device
was used for all readings. Measurements were taken until three
readings that were within 10% of each other were obtained. BP
was calculated as the mean of these three readings. Hypertension
was defined as a systolic BP$140 mmHg, diastolic
BP$90 mmHg, or current antihypertensive medication [26].
Mean arterial pressure (MAP) was calculated as 1/3 the average
SBP plus 2/3 the average DBP.
Pulse wave velocity. Carotid to femoral pulse wave velocity
was measured as a marker of arterial stiffness, a critical
determinant of cardiovascular outcomes in CKD [7,27,28], and
considered the gold standard measurement of AS [12]. Measure-
ments were performed using a VicorderTM device (Skidmore
Medical Ltd, Bristol, UK). The VicorderTM is small, portable,
non-invasive and non-operator dependant making it well suited for
use in community based studies. Readings take only 2–3 minutes
to complete. Assessments were performed after at least 5 minutes
of rest, according to manufacturers’ instructions in the semi-prone
position (at approximately 30u) to prevent venous contamination
of the arterial signal. The participant had a neck-pad placed
around their neck with the pressure pad over the right carotid
area. A blood pressure cuff was placed around the patients’ upper
right thigh. The distance between the supra-sternal notch and the
thigh cuff was measured using the direct method. To eliminate the
potential effect of abdominal obesity on the distance measurement,
an imaginary line was drawn from the supra-sternal notch to the
right shoulder and the measurement to the thigh cuff was made
along the side of the body. The neck-pad and thigh cuff were
inflated by the Vicorder to 60 mmHg and then deflated to obtain
a pressure tracing. Aortic PWV is calculated by the Vicorder by
comparing carotid and femoral pressure tracings after a stable
pattern is obtained. The mild discomfort caused by the inflation of
a cuff placed around the neck precluded us from doing multiple
readings. The intra-observer coefficient of variation for PWV
measurements was 6.3%.
Skin Autofluorescence
Skin autofluorescence (AF), a measure of skin Advanced
Glycation Endproduct (AGE) deposition that has been identified
as a marker of cumulative metabolic stress [29,30,31], was assessed
on the left forearm using an AGE ReaderTM device (DiagnOptics,
Groningen, Netherlands). Three readings were taken and the
average calculated. It was not possible to conduct these readings
on dark skin. Values are expressed in arbitrary units [22].
Albuminuria. Albuminuria was assessed by measuring the
urine albumin to creatinine ratio (ACR) on three consecutive early
morning urine specimens collected prior to the clinic visit and
stored in a refrigerator. Microalbuminuria was defined as a mean
urine ACR of .2.5 mg/mmol in males or .3.5 mg/mmol in
females and overt albuminuria as .30 mg/mmol [23].
Estimation of glomerular filtration rate
(eGFR). Biochemical assessments were performed by autoana-
lyser in a single laboratory. The creatinine assay has been
standardised against an isotope dilution mass spectrometry (IDMS)
method and the 4-variable MDRD equation modified for use with
IDMS standardised creatinine measurement was used to estimate
GFR. This study was commenced prior to publication of the
Determinants of Arterial Stiffness in CKD Stage 3
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CKD-EPI formula and eGFR derived from the MDRD formula
was therefore used for recruitment and baseline study assessments.
The study was approved by the Nottingham Research Ethics
Committee 1 and abided by the principles of the Declaration of
Helsinki. All participants provided written informed consent. The
study was included on the National Institute for Health Research
(NIHR) Clinical Research Portfolio (NIHR Study ID:6632) and
was independently audited by QED Clinical Services in Novem-
ber 2009.
Statistical Analysis
Results presented are a cross sectional analysis of data from the
first study visit. Continuous variables are reported as the mean and
standard deviation (SD) if normally distributed or the median and
inter-quartile range (IQR) if not. A t-test was used to compare two
groups where variables were normally distributed and a Mann U
Whitney test used if not. Pearson’s test was used to assess
univariate correlations with aPWV for variables with normal
distribution or Spearman’s test if distribution was not normal.
Partial correlations were used to correct for MAP. Variables with
skewed distribution (exponential) were log transformed for the
correlations. SPSS version 15.0 was used for univariate analysis.
P,0.05 was considered statistically significant.
Multivariable linear regression analysis, using the forward
stepwise method, was used to identify independent determinants
of arterial stiffness. P,0.05 was used for a variable to enter the
model. The model was built using a hierarchical approach that
introduced variables one-by-one on the basis of biological
plausibility as well as strength of association in univariate analyses
adjusted for age and diabetes. Nested models were tested using the
Akaike Information Criterion (AIC). Models with a smaller AIC
value were selected. An interactive term for age by gender was also
tested in the final model. A scatter plot of regression residuals
versus predicted values and Cook’s Distance plot were used for
testing the assumptions of linear regression and identifying any
outliers. The adjusted R-squared value is reported as a measure of
goodness-of-fit. The regression coefficients (95% Confidence
Intervals) and standardised coefficients (Beta) from the final
multivariable model are presented. STATA version 11.1 was used
for multivariable analysis.
Results
Baseline characteristics are summarised in Table 1. Over a third
of participants were obese (37%). Most (88%) had hypertension
and 65% were treated with a renin angiotensin aldosterone system
inhibitor (RAASi).
Mean aPWV was 9.962 m/sec. Aortic PWV was significantly
higher in participants who were male, had diabetes, had had
previous CVE, had albuminuria (microscopic or overt), were
hypertensive, were not obese (as defined by BMI), had a blood
pressure over 130/80 mmHg or were $75 years of age (Table 2).
People who evidenced increased central fat distribution (central
obesity), anaemia, were receiving antihypertensive medication,
had CKD stage 3B or who had previously smoked also had
significantly higher aPWV (Table 2). Age evidenced the strongest
correlation with aPWV before and after adjusting for MAP
(Table 3). Mean arterial pressure was also strongly correlated with
aPWV. Other significant correlations are shown in Table 3.
Adjustment for MAP produced little change in the correlations.
Multivariable analysis was performed to identify independent
determinants of a higher aPWV (Table 4; adjusted R2= 0.29). The
strongest and most significant of these were age, MAP, diabetes
and BMI. Interestingly, BMI showed a negative relationship with
aPWV. Other relatively weak independent determinants included
serum total protein, log urine ACR and HDL cholesterol. An
interactive term indicated that PWV increased to a greater extent
with age in males versus females.
Discussion
We have identified age as the strongest determinant of arterial
stiffness in this cohort of predominantly elderly patients with CKD
stage 3. Other significant independent determinants of aPWV
included traditional cardiovascular risk factors such as blood
pressure, diabetes, obesity and a marker of dyslipidaemia. Markers
of CKD were associated with aPWV only in univariate analysis
(eGFR) or were weak determinants of aPWV (albuminuria). Our
Table 1. Baseline characteristics.
Females n Males n Total n
Age (years) 73
(66–79)
1037 75
(69–80)*
680 74
(67–79)
1717
Ethnicity white 1014 (98) 1037 661 (97) 680 1675 (98) 1717
Diabetes 158 (15) 1037 129 (19)* 680 287 (17) 1717
Previous CVE 185 (18) 1037 195 (29)* 680 380 (22) 1717
Current smoker 47 (5) 1037 31 (5) 680 78 (4.5) 1717
Previous smoker 407 (39) 1037 444 (65)* 680 851 (50) 1717
BMI (kg/m2) 29.0
(25.6–32.5)
1037 27.8
(25.7–30.5)*
680 28.4
(25.6–31.8)
1717
Systolic BP (mmHg) 133619 1037 136618* 680 134618 1717
Diastolic BP (mmHg)72611 1037 74611* 680 73611 1717
MAP (mmHg) 92612 1037 94611* 680 93612 1717
eGFR (mL/min/
1.73 m2)
54.4
(46.7–61.1)
1037 51.1
(44.1–57.6)*
680 53.3
(45.5–59.8)
1717
HDL Cholesterol
(mmol/L)
1.55
(1.27–1.85)
1032 1.19
(1.00–1.45)*
676 1.40
(1.13–1.71)
1708
Total Cholesterol
(mmol/L)
4.90
(4.10–5.80)
1032 4.20
(3.60–4.98)*
676 4.6
(3.9–5.5)
1708
Serum total protein
(g/L)
74.264.8 1031 74.464.9 677 74.364.9 1708
Serum albumin (g/L)40.563.0 1036 40.963.3* 678 40.763.2 1714
Corrected calcium
(mmol/L)
2.3960.10 1033 2.3560.09* 673 2.3860.10 1706
Phosphate (mmol/L)1.1560.17 1018 1.0560.18* 667 1.1160.18 1685
UACR (mg/mmol) 0.23
(0.00–0.90)
1035 0.63
(0.00–3.27)*
679 0.33
(0.00–1.50)
1714
CKD 3B 208 (20) 1037 194 (29)* 680 402 (23) 1717
aPWV (m/sec) 9.762.0 1037 10.362* 680 9.962 1717
hs CRP (mg/L) 2.23
(1.13–4.67)
1036 2.21
(1.14–4.28)
680 2.22
(1.13–4.50)
1716
Waist to Hip Ratio 0.86
(0.81–0.90)
1037 0.98
(0.94–1.02)*
680 0.91
(0.84–0.97)
1717
SAF (AU) 2.60
(2.30–3.00)
1023 2.73
(2.33–3.18)*
665 2.67
(2.30–3.07)
1688
Data are mean6SD, median (IQR) or number (%).
*P,0.05 versus females.
aPWV= aortic pulse wave velocity; AU=Arbitrary units.; BP = blood pressure;
BMI = body mass index; CKD 3B= eGFR 30–44 mLs/min/1.73 m2;
CVE = cardiovascular event; eGFR = estimated glomerular filtration rate;
HDL = high density lipo-protein; hs CRP= high sensitivity C-reactive protein;
MAP=mean arterial pressure; SAF = skin autofluorescence; UACR= urine
albumin to creatinine ratio.
doi:10.1371/journal.pone.0055444.t001
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data therefore suggest that markers of kidney disease are not
strong determinants of AS in early CKD and that traditional risk
factors for CVD may be more important, or that mechanisms
unrelated to AS mediate the association between early CKD and
increased cardiovascular risk in this population.
Published data regarding the relationship between AS and
CKD appear contradictory. Studies of patients receiving dialysis
or with advanced CKD reported significantly increased AS
compared with the general population [32,33] but results from
studies that included those with earlier stages of CKD are variable.
A number of studies have reported associations with reduced GFR
and increased AS [15,17,34]. In a relatively small study of 102
people with a wide spectrum of CKD (stages 1–5) a clear stepwise
increase corresponding to stage of CKD was reported [15].
Multivariable analysis confirmed an independent association
between GFR and aPWV; however only a small number of
participants (n = 45) had CKD stage 3–4 and GFR was
substantially lower than in our cohort (mean eGFR of 38 mL/
min/1.73 m2). In a larger study of 2564 patients with CKD who
were not receiving dialysis (almost half with diabetes, mean age
60.7 years, mean eGFR 40.7 mL/min/1.73 m2), Townsend et al.
also found an increase in aPWV with declining GFR [17].
Similarly, a population-based study of 767 people (mean age 68
years, eGFR 60.6 mL/min/1.73 m2 and ACR 0.57 mg/mmol)
targeting screening for type 2 diabetes, found that AS increased as
GFR decreased in those with mild CKD (stage 2–3) [34]. In
addition urinary ACR was positively associated with increased AS.
On the other hand Briet et al [18] reported that AS was higher in
patients with CKD than in hypertensive patients without CKD,
but in the analysis of patients with CKD stage 3–5 they did not
find a significant relationship between measured GFR and aPWV.
Similarly, in a study of 150 patients with CKD stages 2–5D,
aPWV was significantly higher in patients with CKD versus
controls without CKD, but aPWV was not higher in those with
more advanced CKD [20]. In another study of patients with
CKD, blood pressure was the major determinant of PWV and
although PWV correlated with GFR in a univariate analysis, GFR
was not an independent determinant of PWV in a multivariable
analysis [35]. Similarly, in 113 patients with CKD, PWV increased
Table 2. aPWV readings in selected subgroups.
Yes No P value
Male 10.362.0 9.762.0 ,0.001
Diabetes 10.362.0 9.862.0 ,0.001
Previous CVE 10.360.7 9.860.6 ,0.001
Albuminuria* 10.362.0 9.862.0 ,0.001
Hypertension{ 10.062.0 9.162.0 ,0.001
BP,130/80 at baseline visit 9.261.7 10.362.1 ,0.001
Obese 9.561.9 10.162.0 ,0.001
Age ,75 years 9.1(8.1–10.3) 10.5(9.4–11.8) ,0.001
Anaemia 10.261.9 9.862 0.003
Central Obesity 9.962 9.561.9 0.003
On antihypertensive medication 10.062.0 9.662.1 0.007
CKD stage 3B 10.162 9.862.1 0.009
Previous Smoker 10.062.1 9.861.9 0.011
Data are presented as mean 6 standard deviation or median (interquartile
range).
aPWV (aortic pulse wave velocity) readings expressed as m/sec.
*Microalbuminuria or greater levels of proteinuria.
CKD 3B = eGFR 30–44 mls/min/1.73 m2; CVE = cardiovascular event;
MAP=Mean arterial pressure;
{=Hypertension at entry into study;
Mann U Whitney tests used where data were not normally distributed.
doi:10.1371/journal.pone.0055444.t002
Table 3. Significant Correlations with aPWV.
Total Cohort
(unadjusted)
Total Cohort
(adjusted for MAP)
r P-value r P-value
Age (years) 0.456* ,0.001 0.461 ,0.001
MAP (mmHg) 0.228 ,0.001 – –
Urine ACR (mg/mmol){ 0.124 ,0.001 0.111 ,0.001
Waist to Hip ratio{ 0.124 ,0.001 0.121 ,0.001
BMI (kg/m2){ 20.122 ,0.001 20.133 ,0.001
Skin autofluorescence{ 0.117 ,0.001 0.133 ,0.001
Total Protein (g/L) 0.084 0.001 0.049 0.046
eGFR (mL/min/1.73 m2) 20.074* 0.002 20.096 ,0.001
hs CRP{ 0.066 0.006 0.057 0.020
HDL Cholesterol (mmol/L){ 20.062 0.010 20.069 0.005
Total Cholesterol (mmol/L){ 20.057 0.018 20.100 ,0.001
*Spearman correlation, otherwise Pearson correlation used. For adjusted values
partial correlations were used.
{= log transformed data. r = correlation coefficient.
ACR= albumin to creatinine ratio; aPWV= aortic pulse wave velocity; BP = blood
pressure; BMI = Body Mass Index; eGFR = estimated glomerular filtration rate;
IMD= Indicies of multiple deprivation; HDL =high density lipo-protein; HS
CRP=High sensitivity C-reactive protein; MAP=Mean arterial pressure.
doi:10.1371/journal.pone.0055444.t003
Table 4. Independent Determinants of higher aPWV.
Total Cohort
Adjusted R2 =0.29
B (95% CI) b p value
Age (10 years) 1.09 (0.94 to 1.24) 0.49 ,0.001
Gender (female) 1.46 (0.07 to 2.85) 0.35 0.04
MAP (10 mmHg) 0.43 (0.35 to 0.50) 0.24 ,0.001
Diabetes Mellitus 0.61 (0.38 to 0.83) 0.11 ,0.001
Body Mass Index (kg/m2) 20.042 (20.058 to
20.025)
20.11 ,0.001
Total serum protein 0.025 (0.0084 to 0.042) 0.06 0.003
{UACR (mg/mmol) 0.060 (0.0061 to 0.11 ) 0.05 0.03
HDL Cholesterol (mmol/L) 20.21 (20.42 to
20.0028)
20.046 0.047
Interactive term age by
gender (F)
20.22 (20.41 to
20.031)
20.39 0.02
B = un-standardised coefficient (95% confidence intervals).
b= standardized coefficient (Beta).
F = female.
{log-transformed data.
aPWV= aortic pulse wave velocity; HDL = high density lipo-protein; MAP =mean
arterial blood pressure; UACR= urine albumin to creatinine ratio.
Independent variables that did not enter the equation were: eGFR, previous
smoker status, past history of cardiovascular event, anaemia, white cell count,
serum potassium, total cholesterol, skin autofluorescence, log urine protein to
creatinine ratio, log high sensitivity CRP, waist to hip ratio, serum glucose.
treatment with inhibitors on the renin angiotensin aldosterone system (RAASi),
antihypertensive treatment.
doi:10.1371/journal.pone.0055444.t004
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with increasing number of components of the metabolic syndrome
irrespective of GFR [36]. In one analysis of data from the
Framingham Heart Study that included 181 patients with early
CKD and characteristics very similar to ours (mean age 70 years,
mean eGFR 51 mL/min/1.73 m2, median urinary ACR 10 mg/
g), AS was not different between those with or without CKD
(defined by reduced GFR) after multivariable adjustment at
baseline. In a longitudinal analysis, increased AS was not
associated with increased risk of developing CKD [6]. On the
other hand, higher aPWV was associated with elevated urinary
albumin excretion at baseline and increased risk of developing
microalbuminuria. Finally, in the Nephro Test cohort of 180
patients with CKD (mean age 59.6years, eGFR 32 mL/min/
1.73 m2) aortic PWV remained stable during 3.5 years of follow
up despite a significant decline in GFR and an increase in
albuminuria. Interestingly, increased carotid circumferential wall
stress and pulse pressure were associated with a greater risk of
progression to ESKD [19]. Taken together, published data show
that arterial stiffness increases in advanced stages of CKD but that
changes are more variable in early stages, probably reflecting
differences in the populations studied, particularly with respect to
age. Thus the lack of an independent negative association between
eGFR and increased aPWV in our study as well as the weak
association between urinary ACR and increased aPWV are
probably attributable to the fact that our study population was
predominantly elderly, the range of eGFR values was relatively
small and albuminuria was present only in a small minority. These
observations are nevertheless important because our study cohort
is representative of the majority of people affected by early stage
CKD, at least in the UK.
Previous studies have also identified age, blood pressure and the
presence of diabetes as determinants of higher aPWV [6,17,20].
Our observation that aPWV increased to a greater extent with age
in males versus females is consistent with data from another study
that identified male gender as an independent determinant of
increased aPWV in a large cohort of people with CKD [17].The
increase in AS with age is proposed to be due to overproduction of
abnormal collagen fibres and a loss of elastin from the extracellular
matrix [9,37]. It is not clear, however, whether this is a time
dependant phenomenon directly related to chronological age or if
it reflects exposure to other risk factors. Hypertension has long
been recognised as a major determinant of arterial stiffness due to
the associated medial hypertrophy [38]. The association between
diabetes and arterial stiffness may be due to accumulation of
advanced glycation endproducts (AGE) that provoke structural
changes in the arterial wall [22] and the generation of reactive
oxygen species that deactivate nitric oxide resulting in endothelial
dysfunction [39].
BMI had an inverse relationship with aPWV. This is surprising
because AS has previously been associated with obesity, particu-
larly abdominal obesity [40], and increased waist to hip ratio was
associated with higher aPWV in our univariate analysis. We have
previously described that BMI decreased with age in our cohort,
likely reflecting a loss of muscle mass [21]. Our observation may
therefore be explained by lower BMI acting as marker of increased
age (the dominant determinant of aPWV) that could not be
completely corrected for in the multi-variable analysis. Further-
more, we have previously shown that measures of obesity that
include central fat distribution are more closely related to
important risk factors in those with CKD than BMI [41].
There are a several limitations to this study. First, this analysis
includes only cross-sectional data and we are therefore unable to
draw any firm conclusions regarding possible causal relationships
between AS and the determinants identified. However, the
planned 10-year follow up of the cohort will allow us to investigate
the factors that contribute to AS prospectively. Many studies have
used aplanation tonometry devices (SphygmoCorTM or Com-
pliorTM) to measure PWV [17,19,20], but these are operator
dependant, time consuming to use and not easy to transport. We
therefore used the more portable VicorderTM device which is also
operator independent and requires only minutes to obtain a
reading. VicorderTM measurements of aPWV have been shown to
be reproducible and correlate well with SphygmoCorTM mea-
surements [42] but as yet there is no agreed method for making
direct comparisons between results obtained by different methods
[43]. A third limitation of our study is the absence of normal
controls. Finally, participants comprised only 22% of people
invited to participate and may therefore not be representative of all
people with CKD stage 3. We were unable for ethical reasons to
obtain data on non-participants but our study population was
similar to a large population of people with CKD stage 3 derived
by pooling data on all patients from several GP databases,
suggesting that our participants were broadly representative of
patients with CKD stage 3 in primary care in the UK, though with
a low proportion of people from ethnic minorities [44]. Strengths
of the study include the large cohort size, robust measures of
eGFR and UACR, and detailed clinical assessment of each
participant. A single operator performed all assessments, elimi-
nating inter-observer variability.
Conclusion
Age was the strongest determinant of arterial stiffness in this
cohort of predominantly elderly patients with CKD stage 3. Other
significant independent determinants of aPWV included tradi-
tional cardiovascular risk factors such as blood pressure, diabetes,
obesity and a marker of dyslipidaemia. Markers of CKD were
associated with aPWV only in univariate analysis (eGFR) or were
weak determinants of aPWV (albuminuria). Long term follow-up
will investigate the importance of arterial stiffness as an
independent risk factor for cardiovascular events in this cohort.
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